Ursodeoxycholic Acid Ameliorates Apoptotic Cascade in the Rotenone Model of Parkinson’s Disease: Modulation of Mitochondrial Perturbations

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Molecular Neurobiology

• Publication date

  2016-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12035-014-9043-8PMID 25502462
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Activation of mitochondrial protease OMA1 by Bax and Bak promotes cytochrome c release during apoptosis

  2014cited by this paper
• The Unexpected Uses of Urso- and Tauroursodeoxycholic Acid in the Treatment of Non-liver Diseases

  2014cited by this paper
• Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity

  2013cited by this paper
• Neuroinflammation and oxidative stress: co-conspirators in the pathology of Parkinson's disease.

  2013cited by this paper
• Dose-dependent antiinflammatory effect of ursodeoxycholic acid in experimental colitis.

  2013cited by this paper
• Rotenone-induced apoptosis and role of calcium: a study on Neuro-2a cells

  2012cited by this paper
• Synergistic Mechanism of Gene Expression and Pathways between Jasminoidin and Ursodeoxycholic Acid in Treating Focal Cerebral Ischemia–Reperfusion Injury

  2012cited by this paper
• Ursodeoxycholic acid suppresses mitochondria-dependent programmed cell death induced by sodium nitroprusside in SH-SY5Y cells.

  2012cited by this paper
• Neurodegeneration and inflammation in Parkinson's disease.

  2012cited by this paper
• Waking Action of Ursodeoxycholic Acid (UDCA) Involves Histamine and GABAA Receptor Block

  2012cited by this paper
• Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.

  2011cited by this paper
• Biliary secretion of S‐nitrosoglutathione is involved in the hypercholeresis induced by ursodeoxycholic acid in the normal rat

  2010cited by this paper
• APOPTOSIS: MOLECULAR MECHANISMS AND PATHOGENICITY

  2010cited by this paper
• Safety, Tolerability, and Cerebrospinal Fluid Penetration of Ursodeoxycholic Acid in Patients With Amyotrophic Lateral Sclerosis

  2010cited by this paper
• Control of mitochondrial apoptosis by the Bcl-2 family

  2009cited by this paper
• Bile acids: regulation of apoptosis by ursodeoxycholic acid

  2009cited by this paper
• Parkinson's disease (vol 373, pg 2055, 2009)

  2009cited by this paper
• Bile acids and apoptosis modulation: an emerging role in experimental Alzheimer's disease.

  2008cited by this paper
• Oxidative and nitrative protein modifications in Parkinson's disease.

  2008cited by this paper
• Antibacterial and anti-atrophic effects of a highly soluble, acid stable UDCA formula in Helicobacter pylori-induced gastritis.

  2008cited by this paper
• Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production.

  2008cited by this paper
• Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder?

  2007cited by this paper
• Ursodeoxycholic acid stimulates cholangiocyte fluid secretion in mice via CFTR-dependent ATP secretion.

  2007cited by this paper
• Ursodeoxycholic acid inhibits interleukin 1 beta [corrected] and deoxycholic acid-induced activation of NF-kappaB and AP-1 in human colon cancer cells.

  2006cited by this paper
• Parkinson's Disease Brain Mitochondrial Complex I Has Oxidatively Damaged Subunits and Is Functionally Impaired and Misassembled

  2006cited by this paper
• Ursodeoxycholic acid inhibits interleukin beta 1 and deoxycholic acid‐induced activation of NF‐κB and AP‐1 in human colon cancer cells

  2006cited by this paper
• Rotenone Model of Parkinson’s Disease: Multiple Brain Mitochondria Dysfunctions after Short-term Systemic Rotenone Intoxication

  2005cited by this paper
• Rotenone Model of Parkinson Disease

  2005cited by this paper
• Ursodeoxycholic acid (UDCA) suppresses liver interleukin 2 mRNA in the cholangitis model.

  2005cited by this paper
• Potential role of ursodeoxycholic acid in suppression of Nuclear factor kappa B in microglial cell line (BV-2)

  2004cited by this paper
• Rotenone-induced Parkinson`s Like Disease: Modulating Role of Coenzyme Q10

  2004cited by this paper
• The Bile Acid Tauroursodeoxycholic Acid Modulates Phosphorylation and Translocation of Bad via Phosphatidylinositol 3-Kinase in Glutamate-Induced Apoptosis of Rat Cortical Neurons

  2004cited by this paper
• Rotenone-induced apoptosis is mediated by p38 and JNK MAP kinases in human dopaminergic SH-SY5Y cells.

  2004cited by this paper
• Neuroprotection by Pergolide Against Levodopa-Induced Cytotoxicity of Neural Stem Cells

  2004cited by this paper
• Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats

  2003cited by this paper
• Apoptosis in Parkinson's disease: Signals for neuronal degradation

  2003cited by this paper
• Tauroursodeoxycholic Acid Prevents Amyloid-β Peptide-Induced Neuronal Death Via a Phosphatidylinositol 3-Kinase-Dependent Signaling Pathway

  2003cited by this paper
• Mitochondrial Complex I Inhibitor Rotenone Induces Apoptosis through Enhancing Mitochondrial Reactive Oxygen Species Production*

  2003cited by this paper
• Tauroursodeoxycholic acid improves the survival and function of nigral transplants in a rat model of Parkinson's disease (vol 11, pg 195, 2002)

  2002cited by this paper
• Tauroursodeoxycholic Acid Improves the Survival and Function of Nigral Transplants in a Rat Model of Parkinson's Disease

  2002cited by this paper
• Antioxidant properties of ursodeoxycholic acid.

  2002cited by this paper
• Neuroprotection by a Bile Acid in an Acute Stroke Model in the Rat

  2002cited by this paper
• Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington's disease

  2002cited by this paper
• Ursodeoxycholic acid diminishes Fas‐ligand–induced apoptosis in mouse hepatocytes

  2002cited by this paper
• Ursodeoxycholic acid in cholestatic liver disease: Mechanisms of action and therapeutic use revisited

  2002cited by this paper
• Rotenone destroys dopaminergic neurons and induces parkinsonian symptoms in rats.

  2002cited by this paper
• Caspases: keys in the ignition of cell death.

  2002cited by this paper
• Tumor necrosis factor‐α and transforming growth factor‐β reflect severity of liver damage in primary biliary cirrhosis

  2002cited by this paper
• Stimulation of ATP secretion in the liver by therapeutic bile acids.

  2001cited by this paper
• A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease.

  2001cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• Functional Modulation of the Glucocorticoid Receptor and Suppression of NF-κB-dependent Transcription by Ursodeoxycholic Acid*

  2001cited by this paper
• Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease.

  2001cited by this paper
• Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria.

  2000cited by this paper
• Role of the mitochondrial membrane permeability transition (MPT) in rotenone-induced apoptosis in liver cells.

  2000cited by this paper
• Pathoanatomy of Parkinson’s disease

  2000cited by this paper
• Bilirubin and Amyloid-β Peptide Induce Cytochrome c Release Through Mitochondrial Membrane Permeabilization

  2000cited by this paper
• Gone but not forgotten

  2000cited by this paper
• Inflammation and Stroke: Putative Role for Cytokines, Adhesion Molecules and iNOS in Brain Response to Ischemia

  2000cited by this paper
• Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation

  1999cited by this paper
• Mammalian caspases: structure, activation, substrates, and functions during apoptosis.

  1999cited by this paper
• Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.

  1998cited by this paper
• Ursodeoxycholic Acid May Inhibit Deoxycholic Acid-Induced Apoptosis by Modulating Mitochondrial Transmembrane Potential and Reactive Oxygen Species Production

  1998cited by this paper
• CFTR regulates outwardly rectifying chloride channels through an autocrine mechanism involving ATP.

  1995cited by this paper
• Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide

  1993cited by this paper
• Basic Techniques for Transmission Electron Microscopy.

  1990cited by this paper
• Differential effects of dopaminergic drugs on open-field behavior of spontaneously hypertensive rats and normotensive Wistar-Kyoto rats.

  1989cited by this paper
• Localization of the ecto-ATPase (ecto-nucleotidase) in the rat hepatocyte plasma membrane. Implications for the functions of the ecto-ATPase.

  1989cited by this paper
• Mitochondrial Complex I Deficiency in Parkinson's Disease

  1989cited by this paper
• Basic Techniques for Transmission Electron Microscopy

  1985cited by this paper

• The role of the gut microbiome in Parkinson’s disease

  2025cites this paper
• Vinpocetine and Lactobacillus Attenuated Rotenone-Induced Parkinson’s Disease and Restored Dopamine Synthesis in Rats through Modulation of Oxidative Stress, Neuroinflammation, and Lewy Bodies Inclusion

  2025cites this paper
• The effects of ursodeoxycholic acid on Parkinson’s disease, a mechanistic review of the recent evidence

  2025cites this paper
• Nanobilosome as custom-tailored modality in addressing Alzheimer’s disease: advancements and translational glitches

  2025cites this paper
• Vitamin D and canagliflozin combination alleviates Parkinson’s disease in rats through modulation of RAC1/NF-κB/Nrf2 interaction

  2025cites this paper
• Health position paper and redox perspectives – Bench to bedside transition for pharmacological regulation of NRF2 in noncommunicable diseases

  2025cites this paper
• Gut-eye axis in ophthalmic diseases: Focus on ocular neurodegeneration.

  2025cites this paper
• The neuroprotective effect of ursodeoxycholic acid in different neurological diseases

  2025cites this paper
• Ursodeoxycholic Acid Attenuates B Cell Susceptibility to SARS-CoV-2 Spike Protein by Interfering Its Binding to ACE2

  2025cites this paper
• Biosynthesis of tauro-ursodeoxycholic acid (TUDCA) in Saccharomyces cerevisiae

  2025cites this paper
• Neuroprotection in Parkinson Disease

  2025cites this paper
• Arisaema cum Bile Mitigate Febrile Seizure in Rats via Inhibition of Neuroinflammation, Regulation of FXR and GABA Signaling Pathway

  2025influential citation
• Mitochondrial Dysfunction in Genetic and Non-Genetic Parkinson’s Disease

  2025cites this paper
• Taurochenodeoxycholic acid activates autophagy and suppresses inflammatory responses in microglia of MPTP-induced Parkinson's disease mice via AMPK/mTOR, AKT/NFκB and Pink1/Parkin signaling pathways mediated by Takeda G protein-coupled receptor 5.

  2025cites this paper
• The role of gut microbiota-mitochondria crosstalk in neurodegeneration: Underlying mechanisms and potential therapies.

  2025cites this paper
• Infant microbes and metabolites point to childhood neurodevelopmental disorders.

  2024cites this paper
• Ageing, Proteostasis, and the Gut: Insights into Neurological Health and Disease.

  2024cites this paper
• Role of Mitochondrial Dysfunctions in Neurodegenerative Disorders: Advances in Mitochondrial Biology

  2024cites this paper
• Excitotoxicity, Oxytosis/Ferroptosis, and Neurodegeneration: Emerging Insights into Mitochondrial Mechanisms

  2024cites this paper
• Gut microbe-derived metabolites and the risk of cardiovascular disease in the METSIM cohort

  2024cites this paper
• Gut Microbiota Metabolite Messengers in Brain Function and Pathology at a View of Cell Type-Based Receptor and Enzyme Reaction

  2024cites this paper
• The Gut-Brain Axis in Alzheimer’s and Parkinson’s Diseases: The Catalytic Role of Mitochondria

  2024cites this paper
• Probiotics and the microbiota-gut-brain axis in neurodegeneration: Beneficial effects and mechanistic insights.

  2024cites this paper
• Bile acid metabolism in health and ageing-related diseases.

  2024cites this paper
• Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases

  2024cites this paper
• Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: Correlation between Nrf2 and HMGB1/TLR4/PI3K/Akt/mTOR signaling.

  2023cites this paper
• Multidirectional associations between the gut microbiota and Parkinson’s disease, updated information from the perspectives of humoral pathway, cellular immune pathway and neuronal pathway

  2023cites this paper
• Gut microbiota-mediated ursodeoxycholic acids regulate the inflammation of microglia through TGR5 signaling after MCAO.

  2023cites this paper
• Mitochondrial dysfunction in Parkinson’s disease – a key disease hallmark with therapeutic potential

  2023cites this paper
• The potential mechanism of gut microbiota-microbial metabolites-mitochondrial axis in progression of diabetic kidney disease

  2023cites this paper
• Novel insight into the etiology of ischemic stroke gained by integrative multiome-wide association study

  2023cites this paper
• Neuroprotective Effect of Tauroursodeoxycholic Acid (TUDCA) on In Vitro and In Vivo Models of Retinal Disorders: A Systematic Review

  2023cites this paper
• Clinical Trial Highlights: Modulators of Mitochondrial Function

  2023cites this paper
• Protective effects of dioscin against Parkinson's disease via regulating bile acid metabolism through remodeling gut microbiome/GLP-1 signaling

  2023cites this paper
• A Double-Blind, Randomized, Placebo-Controlled Trial of Ursodeoxycholic Acid (UDCA) in Parkinson's Disease.

  2023cites this paper
• Therapeutic Viewpoint on Rat Models of Locomotion Abnormalities and Neurobiological Indicators in Parkinson's Disease.

  2023cites this paper
• Farnesoid X receptor is inhibited after ileum transposition in diabetic rats: its hypoglycemic effect

  2023cites this paper
• Role of Microbiota-Modified Bile Acids in the Regulation of Intracellular Organelles and Neurodegenerative Diseases

  2023cites this paper
• Novel insight into the etiology of ischemic stroke gained by integrative transcriptome-wide association study

  2023cites this paper
• The Crosstalk between Microbiome and Mitochondrial Homeostasis in Neurodegeneration

  2023cites this paper
• Coumaric acid ameliorates experimental colitis in rats through attenuation of oxidative stress, inflammatory response and apoptosis

  2022cites this paper
• Precision Medicine in Parkinson’s Disease: From Genetic Risk Signals to Personalized Therapy

  2022cites this paper
• Targeting Mitochondria as a Therapeutic Approach for Parkinson’s Disease

  2022cites this paper
• Metabolomic Biomarkers in Parkinson’s Disease

  2022cites this paper
• Mitochondrial Calcium: Effects of Its Imbalance in Disease

  2022cites this paper
• Ursodeoxycholic acid ameliorates cell migration retarded by the SARS-CoV-2 spike protein in BEAS-2B human bronchial epithelial cells

  2022cites this paper
• N-3 PUFA Ameliorates the Gut Microbiota, Bile Acid Profiles, and Neuropsychiatric Behaviours in a Rat Model of Geriatric Depression

  2022cites this paper
• Curcumin-loaded human endometrial stem cells derived exosomes as an effective carrier to suppress alpha-synuclein aggregates in 6OHDA-induced Parkinson’s disease mouse model

  2022cites this paper
• Distinct Bile Acid Signature in Parkinson's Disease With Mild Cognitive Impairment

  2022cites this paper
• Bile acids and neurological disease.

  2022cites this paper
• Protective Effects of Ursodeoxycholic Acid Against Oxidative Stress and Neuroinflammation Through Mitogen-Activated Protein Kinases Pathway in MPTP-Induced Parkinson Disease

  2022cites this paper
• Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling

  2022cites this paper
• Molecular and Cellular Interactions in Pathogenesis of Sporadic Parkinson Disease

  2022cites this paper
• Emerging insights between gut microbiome dysbiosis and Parkinson's disease: Pathogenic and clinical relevance.

  2022cites this paper
• Changes in the Gut Microbiome and Predicted Functional Metabolic Effects in an Australian Parkinson’s Disease Cohort

  2021cites this paper
• Targeting Mitochondrial Impairment in Parkinson's Disease: Challenges and Opportunities

  2021cites this paper
• Unravelling the role of gut microbiota in Parkinson's disease progression: Pathogenic and therapeutic implications.

  2021cites this paper
• Comprehensive metabolic profiling of Parkinson’s disease by liquid chromatography-mass spectrometry

  2021cites this paper
• Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience

  2021cites this paper
• Grape seed extract improved the fertility-enhancing effect of atorvastatin in high-fat diet-induced testicular injury in rats: involvement of antioxidant and anti-apoptotic effects.

  2021cites this paper
• Gut Microbial Metabolites in Parkinson’s Disease: Implications of Mitochondrial Dysfunction in the Pathogenesis and Treatment

  2021cites this paper
• The role of gut dysbiosis in Parkinson's disease: mechanistic insights andtherapeutic options.

  2021cites this paper
• Connecting the dots between mitochondrial dysfunction and Parkinson’s disorder: focus mitochondria-targeting therapeutic paradigm in mitigating the disease severity

  2021cites this paper
• Do Autophagy Enhancers/ROS Scavengers Alleviate Consequences of Mild Mitochondrial Dysfunction Induced in Neuronal-Derived Cells?

  2021cites this paper
• Bile acid receptors and signaling crosstalk in the liver, gut and brain

  2021cites this paper
• Farnesoid X Receptor Activation in Brain Alters Brown Adipose Tissue Function via the Sympathetic System

  2021cites this paper
• From dried bear bile to molecular investigation: a systematic review of the effect of bile acids on cell apoptosis, oxidative stress and inflammation in the brain, across pre-clinical models of neurological, neurodegenerative and neuropsychiatric disorders.

  2021cites this paper
• Ursodeoxycholic acid as a potential alternative therapeutic approach for neurodegenerative disorders: Effects on cell apoptosis, oxidative stress and inflammation in the brain

  2021cites this paper
• Novel mechanistic insights towards the repositioning of alogliptin in Parkinson's disease.

  2021cites this paper
• Enhancement of anti-inflammatory effect of cattle bile by fermentation and its inhibition of neuroinflammation on microglia by inhibiting NLRP3 inflammasome.

  2021cites this paper
• RECENT TRENDS IN THE TREATMENT OF PARKINSON'S DISEASE

  2021cites this paper
• Ursodeoxycholic and tauroursodeoxycholic acids as antiapoptotic agents: modulation of Parkinson's disease

  2020cites this paper
• Nasal administration of nanoencapsulated geraniol/ursodeoxycholic acid conjugate: Towards a new approach for the management of Parkinson's disease.

  2020cites this paper
• Pharmacokinetics, Safety, and Tolerability of Orally Administered Ursodeoxycholic Acid in Patients With Parkinson's Disease—A Pilot Study

  2020cites this paper
• Ursodeoxycholic acid protects against cisplatin-induced acute kidney injury and mitochondrial dysfunction through acting on ALDH1L2.

  2020cites this paper
• Ursodeoxycholic acid protects dopaminergic neurons from oxidative stress via regulating mitochondrial function, autophagy, and apoptosis in MPTP/MPP+-induced Parkinson's disease.

  2020cites this paper
• The multi‐faceted role of mitochondria in the pathology of Parkinson’s disease

  2020cites this paper
• Ursodeoksikolik Asit’in Farelerde Pentilentetrazol ile Oluşturulan Akut Epileptik Nöbetler Üzerine Etkisinin Araştırılması

  2020cites this paper
• Bile Acid Signaling in Neurodegenerative and Neurological Disorders

  2020cites this paper
• Recent developments in the treatment of Parkinson's Disease

  2020cites this paper
• Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study

  2020cites this paper
• Neurodegeneration in juvenile Iberian pigs with diet-induced non-alcoholic fatty liver disease.

  2020cites this paper
• Status and future directions of clinical trials in Parkinson's disease.

  2020cites this paper
• The role of KATP channel blockade and activation in the protection against neurodegeneration in the rotenone model of Parkinson's disease.

  2020cites this paper
• Anti-convulsant effects of cultures bear bile powder in febrile seizure via regulation of neurotransmission and inhibition of neuroinflammation.

  2020cites this paper
• Ursodeoxycholic acid inhibits glioblastoma progression via endoplasmic reticulum stress related apoptosis and synergizes with the proteasome inhibitor bortezomib.

  2020cites this paper
• Ursodeoxycholic acid and its unexpected application areas

  2020cites this paper
• Ursodeoksikolik Asit’in Farelerde Pentilentetrazol ile Oluşturulan Akut Epileptik Nöbetler Üzerine Etkisinin Investigation of the Effect of Ursodeoxycholic Acid on Pentylenetetrazole-induced Acute Epileptic Seizures in Mice

  2020cites this paper
• Rotenone neurotoxicity: Relevance to Parkinson's disease

  2020cites this paper
• Cold‐inducible protein RBM3 mediates hypothermic neuroprotection against neurotoxin rotenone via inhibition on MAPK signalling

  2019cites this paper
• The Biosynthesis, Signaling, and Neurological Functions of Bile Acids

  2019cites this paper
• Hydroxychloroquine antiparkinsonian potential: Nurr1 modulation versus autophagy inhibition

  2019cites this paper
• Interfering with miR-24 alleviates rotenone-induced dopaminergic neuron injury via enhancing autophagy by upregulating DJ-1

  2019cites this paper
• New insights into the complex role of mitochondria in Parkinson's disease.

  2019cites this paper
• Potential effects of ursodeoxycholic acid on accelerating cutaneous wound healing

  2019cites this paper
• Review: The bile acids urso- and tauroursodeoxycholic acid as neuroprotective therapies in retinal disease

  2019cites this paper
• Ursodeoxycholic acid: A promising therapeutic target for inflammatory bowel diseases?

  2019cites this paper
• Neuroprotective effects of cordycepin with anti-apoptosis mechanism based on mitochondrial pathway in rotenone-induced parkinsonism rat model.

  2019cites this paper
• UDCA, NorUDCA, and TUDCA in Liver Diseases: A Review of Their Mechanisms of Action and Clinical Applications.

  2019cites this paper
• Montelukast attenuates rotenone‐induced microglial activation/p38 MAPK expression in rats: Possible role of its antioxidant, anti‐inflammatory and antiapoptotic effects

  2018cites this paper